AU Patent

AU2024263986A1 — Dose initiation for schizophrenia or bipolar i disorder treatment with aripiprazole

Assigned to Otsuka Pharmaceutical Co Ltd · Expires 2025-10-09 · 1y expired

What this patent protects

The present disclosure is directed to methods of dose initiation for an aripiprazole treatment to a patient in need thereof by administering two, separate injections of aripiprazole with a first aripiprazole injection of a long acting injectable (LAI) and a second aripiprazole in…

USPTO Abstract

The present disclosure is directed to methods of dose initiation for an aripiprazole treatment to a patient in need thereof by administering two, separate injections of aripiprazole with a first aripiprazole injection of a long acting injectable (LAI) and a second aripiprazole injection of a once-monthly injectable (AOM) on a first day of the aripiprazole treatment, and a single dose of oral aripiprazole. Maintenance dosing occurs about two months after the first day of the aripiprazole treatment using a maintenance dose of the LAI. The present methods are applicable to both the deltoid and gluteal administration sites.

Drugs covered by this patent

Patent Metadata

Patent number
AU2024263986A1
Jurisdiction
AU
Classification
—
Expires
2025-10-09
Drug substance claim
No
Drug product claim
No
Assignee
Otsuka Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.